The most developed adverse outcome pathways arefor AhR and ER, whereby their activation has been connected to earlymortality, several cancers, preeclampsia, cognitive decline, liverfibrosis and steatosis, and reproductive dysfunction. The gene discussed is AHR; the disease is steatosis.